An old-age drug RLF-100 or Aviptadil, used for treatment for Acute Respiratory Distress Syndrome and chronic lung diseases, has now been proposed for treatment of COVID-19 infection.
Daily Current Affairs Quiz 2020
Key-Points
According to a report by the IE, the drug is being probed as some studies indicated that it is able to halt the replication of viruses in lungs.
RLF-100, also called Aviptadil, is a formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP).
VIP is released throughout the body, but remains mostly concentrated in lungs.
It is produced by immune cells and nerve endings and acts as a neurotransmitter. It helps improve muscle activity and blood flow in gastrointestinal tract. Studies have shown VIP has anti-inflammatory and anti-cytokine activity properties.
RLF-100 is not a new finding. It was discovered in 1970 by Dr Sami Said, a pulmonary medicine specialist.
